PBSV - Pharma-Bio Serv, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.8500
+0.0899 (+11.83%)
As of 3:19PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.7601
Open0.7900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.7900 - 0.8500
52 Week Range0.6000 - 1.2500
Volume1,100
Avg. Volume1,164
Market Cap19.547M
Beta (3Y Monthly)0.14
PE Ratio (TTM)3.97
EPS (TTM)0.2140
Earnings DateJun 14, 2019
Forward Dividend & Yield0.30 (34.88%)
Ex-Dividend Date2018-10-12
1y Target Est2.25
Trade prices are not sourced from all markets
  • ACCESSWIRE

    Pharma-Bio Serv Announces Results for the Three and Nine Months Ended July 31, 2019

    DORADO, PUERTO RICO / ACCESSWIRE / September 16, 2019 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer ...

  • ACCESSWIRE

    Pharma-Bio Serv Announces Results for the Quarter Ended April 30, 2019

    DORADO, PUERTO RICO / ACCESSWIRE / June 14, 2019 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced revenues from continuing operations for the three and six months ended April 30, 2019 were $5.2 and $9.7 million, respectively, an increase of approximately $1.4 and $2.2 million, or 37% and 30%, respectively, when compared to the same periods last year. Net income from continuing operations for the three and six months ended April 30, 2019 was approximately $0.7 and $1.2 million, respectively, an improvement of $0.7 and $3.7 million when compared to the same periods last year, respectively.

  • Zacks Small Cap Research

    PBSV: Lab Sale Proving To Be Wise Move As Profitability Continues To Improve

    As we await the reporting of Pharma-Bio Serve, Inc.’s (PBSV) fiscal Q2 2019 results (ending April 30th), which will likely happen either late next week or early the following week, we review their recent financial highlights. The benefit to revenue growth is even more apparent now that we can compare year-over-year financial results on pre and post-lab sale bases. Gross margin in fiscal 2017 with the lab included was 23%, but (pro forma for) ex-lab, it was 29%.

  • ACCESSWIRE

    Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2019

    DORADO, PUERTO RICO / ACCESSWIRE / March 18, 2019/ Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced revenues from continuing operations for the quarter ended January 31, 2019 were $4.6 million, an increase of $0.8 million, or 23%, when compared to the same period last year. Net income from continuing operations for the quarter ended January 31, 2019 was approximately $471,000 compared to a net loss from continuing operations of $2.5 million for the same period last year. After considering last year's non-recurring 2018 US Tax Reform $2.7 million Transition Tax charge, the increase in net income from continuing operations is mainly attributable to the improvement in revenue and related gross margin.

  • Zacks Small Cap Research

    PBSV: With Lab Sold, Expect Profitability To Improve

    Pharma-Bio Serv, Inc. (PBSV) filed their 10-K for their 2018 fiscal year ending October 31, 2018. As such and as we had opined in our initial report following news of PBSV’s plans to sell the lab, the divestiture appears to be proving to be a sensible and shareholder-friendly decision. While we had previously made substantial modifications to our modeled cost of services and OpEx, reflecting what we had anticipated would be a significant reduction of fixed and other overhead-type expenses related to the lab, based on the 2018 10-K, we think that we did not go far enough (see our discussion of lab-related depreciation and amortization below).

  • ACCESSWIRE

    Pharma-Bio Serv Announces Results for the Year Ended October 31, 2018

    DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2019/ Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced net revenues from continuing operations for the year ended October 2018 were $17.8 million, an increase of $4.5 million, or 34%, when compared to last year. On September 17, 2018, the Company sold substantially all of its laboratory business assets (the "Laboratory Assets" or the "Discontinued Operation"). During the current fiscal year, the Company was affected by the recent US Tax Reform provisions, including an estimated one-time non-recurring Transition Tax of $2.7 million.